Search Results | Cancer Research | American Association for Cancer Research

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Abstract LB-241: Genomic characterization of breast cancer cells resistant to the histone deacetylase inhibitor romidepsin

Fatima G. Ali-Rahmani, Robert Robey, Justin Lack, Bethelihem Tebase, Susan Bates, Michael Gottesman

Cancer Res (2018) 78 (13_Supplement): LB-241.

DOI: https://doi.org/10.1158/1538-7445.AM2018-LB-241

Published: 01 July 2018

View article

Journal Articles

Abstract 2075: Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors

Alexander Koshkaryev, Jonathan Fitzgerald, Jaeyeon Kim, Ashish Kalra, Walid Kamoun, Sarah Blanchette, Lia Luus, Stephan Klinz, Ozan Alkan, Tad Kornaga, Susan Bates, Yves Pommier, Daryl C. Drummond

Cancer Res (2016) 76 (14_Supplement): 2075.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2075

Published: 15 July 2016

View article

Journal Articles

Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies

Hee-Sheung Lee, Nicholas C.O. Lee, Natalay Kouprina, Jung-Hyun Kim, Alex Kagansky, Susan Bates, Jane B. Trepel, Yves Pommier, Dan Sackett, Vladimir Larionov

Cancer Res (2016) 76 (4): 902–911.

DOI: https://doi.org/10.1158/0008-5472.CAN-15-1617

Published: 14 February 2016

View article

Includes: Supplementary data

Journal Articles

Abstract 3399: Resistance to the histone deacetylase inhibitor romidepsin is associated with degradation of Bim following MAPK pathway activation.

Arup R. Chakraborty, Rob Robey, Zhirong Zhan, Victoria Luchenko, Michael Gottesman, Nathan Collie, Jean-Pierre Gillet, Richard Piekarz, Andrew Kossenkov, Louise Showe, Susan Bates

Cancer Res (2013) 73 (8_Supplement): 3399.

DOI: https://doi.org/10.1158/1538-7445.AM2013-3399

Published: 15 April 2013

View article

Journal Articles

Abstract #3882: Drug resistant cancer cells with high expression of ABCG2 escape microRNA-mediated repression

Kenneth To, Robert Robey, Turid Knutsen, Zhirong Zhan, Thomas Ried, Susan Bates

Cancer Res (2009) 69 (9_Supplement): 3882.

Published: 01 May 2009

View article

Journal Articles

Reversal of ABCB1- and ABCG2-mediated MDR by erlotinib (tarceva, OSI-774)

Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Qiu-Sheng Si, Robert Robey, Susan Bates, Si-Rong Wang, Christine Chim, Tong Shen, Amit Tiwari, Charles Ashby, Liwu Fu, Suresh Ambudkar, Zhe-Sheng Chen

Cancer Res (2008) 68 (9_Supplement): 3247.

Published: 01 May 2008

View article

Journal Articles

Regulation of ABCG2 expression at 3'-untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in resistant cancer cells

Kenneth To, Zhirong Zhan, Susan Bates

Cancer Res (2008) 68 (9_Supplement): 2457.

Published: 01 May 2008

View article

Journal Articles

Differential effects of the EGFR tyrosine kinase inhibitor AG1478 on the function of ABCB1 and ABCG2

Zhi Shi, Amit Tiwari, Suneet Shukla, Robert Robey, Smitaben Parmar, In-Wha Kim, Susan Bates, Qiusheng Si, Curtis Goldblatt, Ioana Abraham, Liwu Fu, Nick Shao, Mimi Chen, Annie Zhang, Suresh Ambudkar, Zhe-Sheng Chen

Cancer Res (2008) 68 (9_Supplement): LB-186.

Published: 01 May 2008

View article

Journal Articles

Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228

Richard Piekarz, Erin Gardner, Zhirong Zhan, Victoria Luchenko, Seth Steinberg, David Liewehr, Kenneth Steadman, Robin Frye, William Figg, Miles Prince, Steve Allen, Jasmine Zain, Mark Kirschbaum, Susan Bates

Cancer Res (2008) 68 (9_Supplement): 5831.

Published: 01 May 2008

View article

Journal Articles

The novel epothilone ixabepilone reduces the growth rate constants of renal carcinoma tumors in comparison with a placebo: Description of a novel algorithm to assess therapeutic efficacy

wilfred stein, Maureen Edgerly, Hui Huang, Michael Menefee, Susan Bates, Tito Fojo

Cancer Res (2008) 68 (9_Supplement): 5829.

Published: 01 May 2008

View article

Journal Articles

Predictive markers for response to EGFR inhibitors in the NCI60 cell lines

Wanqing Liu, Susan Bates, Mark Ratain

Cancer Res (2007) 67 (9_Supplement): 939.

Published: 01 May 2007

View article

Journal Articles

MicroRNA involvement in breast cancer multidrug resistance

Zhongxing Liang, Hui Wu, James Xia, Yuhua Li, Nick Wagar, Aizhi Zhu, Sijia Wang, Dean Blevins, Younghyoun Yoon, Santosh Reddy, Jeanine Southerland, Stefania Scala, Susan Bates, Hyunsuk Shim

Cancer Res (2007) 67 (9_Supplement): 2284.

Published: 01 May 2007

View article

Journal Articles

Romidepsin causes QTc-interval prolongation in mice lacking Abcb1-type P-glycoprotein

Tristan Sissung, Reuben Howden, Haiqing Li, Richard Piekarz, Susan Bates, Douglas Price, Steven Kleeberger, Alex Sparreboom, William Figg

Cancer Res (2007) 67 (9_Supplement): 923.

Published: 01 May 2007

View article

Journal Articles

The multidrug transporter ABCG2: a molecular target during early stages of development of multidrug resistance in breast cancer cells

Anna Maria Calcagno, Jennifer Fostel, Kenneth To, Scott Martin, Katherine Chewning, Chung-Pu Wu, Susan Bates, Natasha Caplen, Suresh Ambudkar

Cancer Res (2007) 67 (9_Supplement): 2333.

Published: 01 May 2007

View article

Journal Articles

Tumor growth rate constants derived from data gathered while patients are on clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data

wilfred stein, Susan Bates, William Figg, William Dahut, Tito Fojo

Cancer Res (2007) 67 (9_Supplement): 2662.

Published: 01 May 2007

View article

Journal Articles

Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors

Mikhail V. Blagosklonny, Shana Trostel, Ganesh Kayastha, Zoya N. Demidenko, Lyubomir T. Vassilev, Larisa Y. Romanova, Susan Bates, Tito Fojo

Cancer Res (2005) 65 (16): 7386–7392.

DOI: https://doi.org/10.1158/0008-5472.CAN-04-3433

Published: 15 August 2005

View article

Journal Articles

The histone deacetylase inhibitor FK228 can increase adenovirus transgene expression in human LOX IMVI melanoma xenografts

Merrill E. Goldsmith, Alian Aguila, Michael C. Alley, William R. Waud, Susan Bates, Tito Fojo

Cancer Res (2005) 65 (9_Supplement): 313.

Published: 01 May 2005

View article

Journal Articles

Transcriptional therapy for neuroblastoma (NB) and ewing’s sarcoma (ES)- the HDAC inhibitor depsipeptide decreases N-myc (NB) and c-myc (ES) levels and inhibits growth in both tumors

Jyoti Panicker, Kenneth Steadman, Susan Bates, Carol J. Thiele

Cancer Res (2005) 65 (9_Supplement): 693.

Published: 01 May 2005

View article

Journal Articles

Human half ABC transporter ABCG2 (BCRP, MXR, ABCP) is not a homodimer

Junkang Xu, Yang Liu, Susan Bates, Jian-Ting Zhang

Cancer Res (2004) 64 (7_Supplement): 118–119.

Published: 01 April 2004

View article

Journal Articles

The histone deacetylase inhibitor FK228 can increase the levels of coxsackie-adenovirus receptor (CAR) in human xenografts in mouse model systems.

Merrill E. Goldsmith, Alian Aguila, Santhi J. Gollapalli, Michael C. Alley, William R. Waud, Susan Bates, Tito Fojo

Cancer Res (2004) 64 (7_Supplement): 540–541.

Published: 01 April 2004

View article

NARROW

Abstract LB-241: Genomic characterization of breast cancer cells resistant to the histone deacetylase inhibitor romidepsin

Abstract 2075: Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors

Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies

Abstract 3399: Resistance to the histone deacetylase inhibitor romidepsin is associated with degradation of Bim following MAPK pathway activation.

Abstract #3882: Drug resistant cancer cells with high expression of ABCG2 escape microRNA-mediated repression

Reversal of ABCB1- and ABCG2-mediated MDR by erlotinib (tarceva, OSI-774)

Regulation of ABCG2 expression at 3'-untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in resistant cancer cells

Differential effects of the EGFR tyrosine kinase inhibitor AG1478 on the function of ABCB1 and ABCG2

Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228

The novel epothilone ixabepilone reduces the growth rate constants of renal carcinoma tumors in comparison with a placebo: Description of a novel algorithm to assess therapeutic efficacy

Predictive markers for response to EGFR inhibitors in the NCI60 cell lines

MicroRNA involvement in breast cancer multidrug resistance

Romidepsin causes QTc-interval prolongation in mice lacking Abcb1-type P-glycoprotein

The multidrug transporter ABCG2: a molecular target during early stages of development of multidrug resistance in breast cancer cells

Tumor growth rate constants derived from data gathered while patients are on clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data

Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors

The histone deacetylase inhibitor FK228 can increase adenovirus transgene expression in human LOX IMVI melanoma xenografts

Transcriptional therapy for neuroblastoma (NB) and ewing’s sarcoma (ES)- the HDAC inhibitor depsipeptide decreases N-myc (NB) and c-myc (ES) levels and inhibits growth in both tumors

Human half ABC transporter ABCG2 (BCRP, MXR, ABCP) is not a homodimer

The histone deacetylase inhibitor FK228 can increase the levels of coxsackie-adenovirus receptor (CAR) in human xenografts in mouse model systems.

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only